AzTrials
AzTrials

Multiple SclerosisEarly Phase 1NCT04096443

Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis

A Early Phase 1 study testing Fecal microbial transplant (FMT) in people with Multiple Sclerosis, run by Griffin Hospital at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this pilot study is to determine whether fecal microbial transplant (FMT) has the potential to be an effective, safe and tolerable therapy for the treatment of multiple sclerosis (MS). The investigators plan to gather preliminary data in a small cohort of 10 to 15 adults with MS. Read more about this study

Who is it for?
Ages 18 to 55 years
Conditions the study is for
Multiple Sclerosis
What is being tested?
Fecal microbial transplant (FMT)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
9 participants
Where
1 siteUnited States
Study dates
28 Oct 2019to 30 Dec 2024
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Diagnosis of clinically definite multiple sclerosis (CDMS) by 2017 McDonald Criteria
  • Ages between 18 and 55 years, inclusive;
  • Expanded Disability Status Score (EDSS) between 1.0 and 6.5.
  • Currently untreated with any disease-modifying therapy (DMT) or currently being treated with glatiramer acetate or interferon beta.
  • Ability to travel to Griffin Hospital for 8 visits over a 5-month period

Who cannot join

  • Inability to give consent;
  • Non-fluency in English;
  • Inability to adhere to the protocol;
  • Inability (e.g., dysphagia) to or unwillingness to swallow capsules;
  • Active gastrointestinal infection at the time of enrollment;
  • Use of antibiotics or corticosteroids within three months of study entry;
Show all 33Show fewer
  • Requiring or anticipating antibiotic use during the four weeks after study entry;
  • MS relapse within one month of study entry;
  • Previous use of any of the following FDA-approved disease-modifying drugs within 12 months of study entry, including natalizumab, fingolimod, siponimod, ozanimod, teriflunomide, diroximel, ocrelizumab, ofatumumab, and/or dimethyl fumarate; or any of the following off-label therapies, including rituximab and cyclophosphamide;
  • Any previous use of the following FDA-approved DMTs, including mitoxantrone, alemtuzumab, and cladribine;
  • IV immunoglobulin or plasma exchange within six months prior to study entry;
  • Known or suspected toxic megacolon and/or known small bowel ileus;
  • Major gastrointestinal surgery (e.g., significant bowel resection) within 3 months prior to enrollment (this does not include appendectomy or cholecystectomy);
  • History of total colectomy or bariatric surgery;
  • Concurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy;
  • Anticipated life expectancy of less than six months;
  • Concomitant other known autoimmune diseases;
  • Concomitant pulmonary, cardiac, gastrointestinal (except as noted above) (Crohns, Colitis, inflammatory bowel, intestinal blockage), hepatic, dermatological or genitourinary disease.
  • Moderate to severe dysphagia;
  • History of alcohol abuse, as defined by the following criteria:
  • Men: 5 or more alcoholic beverages per session or day, or 15 or more per week; Women: 4 or more alcoholic beverages per session or day, or 8 or more per week;
  • History of illicit drug abuse, e.g., of cocaine, heroin, PCP, and/or narcotic substances;
  • Grade 1 or greater lymphopenia, as measured at baseline/clinical screening;
  • Liver Function Tests (LFTs) greater than 1½ times upper limits of normal, as measured at baseline/clinical screening;
  • History of use of FMT or microbiome-based products (excluding probiotics) at any time, excluding this study;
  • History of severe anaphylactic or anaphylactoid food allergy;
  • History of solid organ transplantation;
  • Risk for Cytomegalovirus (CMV) or Epstein Barr virus (EBV) associated disease (at investigator's discretion, e.g., immunocompromised and negative (immunoglobulin gamma) IgG testing for CMV or EBV);
  • Women who are pregnant, lactating, planning to become pregnant, and/or not using an effective method of contraception (women of childbearing potential will undergo a pregnancy test, and will be excluded from the study if results are positive);
  • Any allergies to neomycin or similar antibiotics such as amikacin (Amikin), gentamicin (Garamycin), kanamycin (Kantrex), paromomycin (Humatin, Paromycin), streptomycin, or tobramycin (Nebcin, Tobi);
  • Any condition that would jeopardize the safety or rights of the subject, would make it unlikely for the subject to complete the study, or would confound the study results.
  • Household contacts, including children under the age of 5 years, pregnant women, any person with an immunocompromised condition or on medications causing immunosuppression or persons 70 years or older;
  • Failure to document a COVID-19 vaccine series at least two weeks prior to study entry.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Griffin Hospital

    Derby, Connecticut, 06418

Other trials in United States

About this study

Official title: A Pilot Study of Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis

The goal of this pilot study is to determine whether fecal microbial transplant (FMT) has the potential to be an effective, safe and tolerable therapy for the treatment of multiple sclerosis (MS). The investigators plan to gather preliminary data in a small cohort of 10 to 15 adults with MS.

Read the detailed description

The specific aims are to:

  1. Determine the tolerability of a single dose of 30 capsules in a group of adults with MS
  2. Determine whether any unexpected outcomes arise in participants who successfully complete an FMT procedure consisting of a single dose of 30 capsules
  3. Determine whether successfully completed FMT leads to engraftment of donor microbiome in participants
  4. If the FMT leads to engraftment of donor microbiome in participants, determine whether participants revert back to previous microbiome profiles, and if so, at what time point
  5. Determine whether engrafted species following the FMT, if detected, result in any changes in immune or metabolomic parameters relative to baseline
  6. Determine whether the FMT has any adverse impact, relative to baseline, on study participants' self-reported levels of fatigue, mental well-being, and health-related qualify of life
  7. Determine whether the FMT has any adverse impact, relative to baseline, on study participants' neurological status, relative to baseline

The study population will consist of adults with clinically definite MS who are currently untreated with any disease-modifying therapy or are being treated with glatiramer acetate or interferon beta. The research team will offer study participants a single FMT procedure in the form of 30 oral capsules which contain fecal material. Study participants will visit Griffin Hospital facilities 8 times. The first visit will involve a clinical screening. Of the 7 remaining visits, 6 will involve data collection and one will involve the FMT procedure.

Being tested
Fecal microbial transplant (FMT)
Keywords
Fecal microbial transplant, FMT, Pilot study
Medical subject headings
Multiple Sclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fecal microbial transplant (FMT)Biological

    Oral fecal microbial transplant capsules

Study groups in NCT04096443
Study groupRoleWhat they receive
InterventionExperimentalFecal microbial transplant capsules
Receives: Biological: Fecal microbial transplant (FMT)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in engraftment of donor microbiome in stool samples

    Evidence of engraftment as measured by 16s rRNA microbiome sequencing

    Measured: Pre-FMT and 4 time points post-FMT (3-7 days, 10-15 days, 40-45 days, 100-110 days)

Secondary outcomes (7)

  1. Change in immune markers in blood samples assessed using assays of lymphocyte phenotyping and intracellular cytokines

    Phenotyping will be performed: for T cells - TCRβ, TCRγ, CD4, CD8, CD25, CD44, CD62L, CD69, PD1, CTLA4; for B cells - B220, CD19, CD21, CD23, CD1d, CD5, IgA, IgG1, IgG2a(c), IgG2b; for DCs - CD11c, CD11b, BDCA1, CD8, CD103, CD205 and CD86. The intracellular cytokine (ICC) panel will be IL-6, IL-10, IL-12, IL-17, TNFα, and IFNγ.

    Measured: Pre-FMT and 2 time points post-FMT (40-45 days, 100-110 days)

  2. Change in neurological status using Kurtzke Functional Systems Scale (FSS)

    The FSS uses a set of single-item ordinal clinical rating scales to rate levels of function in seven domains (pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, and cerebral/mental). Each single item scale ranges from 0 to 5 or 6 (0 = "normal;" 5 or 6 represents the worst level of function; and 9 = "unknown"). For each single item scale, scores representing the highest level of function are as follows: pyramidal: 6 = "quadriplegia"; cerebellar: 5 = "unable to perform coordinated movements due to ataxia"; brainstem: 5 = "inability to swallow or speak"; sensory: 6 = "sensation essentially lost below the head"; bowel and bladder: 6 = loss of bowel and bladder function"; visual: 6 = "grade 5 plus maximal visual acuity of better eye of 20/60 or less"; cerebral/mental: 5 = "dementia or chronic brain syndrome - severe or incompetent." The ratings are used in conjunction with observations and information concerning gait and use of assistive devices to rate the EDSS.

    Measured: Pre-FMT and 4 time points post-FMT (3-7 days, 10-15 days, 40-45 days, 100-110 days)

  3. Change in neurological status using Kurtzke Expanded Disability Status Scale (EDSS)

    The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS) in half-point increments.

    Measured: Pre-FMT and 4 time points post-FMT (3-7 days, 10-15 days, 40-45 days, 100-110 days)

  4. Change in self-reported health-related quality of life assessed using the Health Status Questionnaire Short-Form 36 (SF-36)

    The SF-35 has 36 questions. It has a single item covering change in health status over the last year and 8 multi-item scales. The scoring system is relatively complex and generates 8 subscales and 2 summary scores. The 8 subscales are: physical functioning, role limitations due to physical problems, bodily pain, general health perceptions, vitality, social functioning, role-limitations due to emotional problems, and mental health. Two summary scales (Physical and Mental) have been derived using factor analytic methods. Scales are set up so that a higher score indicates better health. To achieve this, responses on 10 items are recoded before being added to other items on the same scale. Raw scale scores are then transformed to a 0-100 scale.

    Measured: Pre-FMT and 3 time points post-FMT (10-15 days, 40-45 days, 100-110 days)

  5. Change in self-reported mental health status assessed using Mental Health Inventory (MHI)

    The MHI consists of 18 items and assesses several domains of mental health. The scoring system generates 4 subscale scores (Anxiety, Depression, Behavioral Control, and Positive Affect) and 1 total score. The subscale and total scores range from 0-100, with higher scores indicating better mental health.

    Measured: Pre-FMT and 3 time points post-FMT (10-15 days, 40-45 days, 100-110 days)

  6. Change in self-reported levels of fatigue assessed using Modified Fatigue Impact Scale (MFIS)

    The MFIS provides an assessment of the effects of fatigue on physical, cognitive, and psychosocial function. It consists of 21 items. The items be aggregated into 3 subscales (Physical, Cognitive, and Psychosocial), as well as into a total MFIS score. All items are scaled so that higher scores indicate a greater impact of fatigue on a patient's activities. The physical subscale can range from 0-36. The cognitive subscale can range from 0-40. The psychosocialsub scale can range from 0-8. The Total MFIS score can range from 0-84.

    Measured: Pre-FMT and 3 time points post-FMT (10-15 days, 40-45 days, 100-110 days)

  7. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Measured by subject's ability to consume capsules as directed without vomiting or adverse side effects (as opposed to mild side effects)

    Measured: Day of FMT procedure and 5 time points post-FMT (1 day, 3-7 days, 10-15 days, 40-45 days, 100-110 days), or any time the study team is contacted by subjects who report adverse side effects

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Sep 2019
  2. Study start28 Oct 2019
  3. Primary completion21 Dec 2024
  4. Study completion30 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Pre/post pilot investigational study
Masking
None (open label)
Enrolment
9 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04096443
Sponsor's protocol ID
2018-09
Status last verified
Sep 2026
First submitted
7 Aug 2019
Last updated
1 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Fecal microbial transplant (FMT) in people with Multiple Sclerosis, run by Griffin Hospital at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 33 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in engraftment of donor microbiome in stool samples (time frame: Pre-FMT and 4 time points post-FMT (3-7 days, 10-15 days, 40-45 days, 100-110 days)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04096443.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in